Cargando…
Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis
OBJECTIVES: Soluble urokinase plasminogen activated receptor (suPAR) is a biomarker that may predict the occurrence of focal segmental glomerulosclerosis (FSGS); however, there is still controversy about whether suPAR can predict FSGS. In this study, we performed a systematic evaluation and meta-ana...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797292/ https://www.ncbi.nlm.nih.gov/pubmed/31594897 http://dx.doi.org/10.1136/bmjopen-2019-031812 |
_version_ | 1783459790478901248 |
---|---|
author | Shuai, Tiankui Pei Jing, Yan Huang, Qiangru Xiong, Huaiyu Liu, Jingjing Zhu, Lei Yang, Kehu Jian, Liu |
author_facet | Shuai, Tiankui Pei Jing, Yan Huang, Qiangru Xiong, Huaiyu Liu, Jingjing Zhu, Lei Yang, Kehu Jian, Liu |
author_sort | Shuai, Tiankui |
collection | PubMed |
description | OBJECTIVES: Soluble urokinase plasminogen activated receptor (suPAR) is a biomarker that may predict the occurrence of focal segmental glomerulosclerosis (FSGS); however, there is still controversy about whether suPAR can predict FSGS. In this study, we performed a systematic evaluation and meta-analysis to prove whether suPAR can predict FSGS, and to detect a threshold concentration of suPAR that can be used to diagnose FSGS. In addition, a threshold concentration of suPAR for the diagnosis of FSGS was proposed. DESIGN: Systematic review and meta-analysis. DATA SOURCES: We systematically searched PubMed, Embase, Cochrane Library, Web of Science and China Biology Medicine databases for studies published from the inception dates to 1 December 2018. ELIGIBILITY CRITERIA: (1) Data involving the suPAR level were from blood samples; (2) FSGS was diagnosed by biopsy; and (3) randomised controlled trials, cohort studies, case–control studies and cross-sectional studies. DATA EXTRACTION AND SYNTHESIS: Initially, a total of 364 studies were searched, among which 29 studies were finally included. In addition, seven studies described the cut-off value of suPAR, which ranged from 2992.6 to 5500 pg/mL. RESULTS: The results showed that the suPAR levels in the primary FSGS group were significantly higher when compared with that in the normal control group (p<0.001; standard mean difference (SMD): 2.56; 95% CI 1.85 to 3.28), and significant differences were observed in the secondary FSGS and in the normal control group (p<0.001; SMD: 1.68; 95% CI 1.37 to 1.98). A suPAR concentration of 3000 pg/mL may be the best threshold for the diagnosis of primary FSGS (sensitivity=0.72; specificity=0.88; area under the curve=0.85). CONCLUSION: Our results suggested that suPAR might be a potential biomarker for predicting primary and secondary FSGS. In addition, our data showed that a suPAR concentration of 3000 pg/mL might be used as a threshold for the diagnosis of FSGS. TRIAL REGISTRATION NUMBER: CRD42019120948. |
format | Online Article Text |
id | pubmed-6797292 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-67972922019-10-31 Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis Shuai, Tiankui Pei Jing, Yan Huang, Qiangru Xiong, Huaiyu Liu, Jingjing Zhu, Lei Yang, Kehu Jian, Liu BMJ Open Renal Medicine OBJECTIVES: Soluble urokinase plasminogen activated receptor (suPAR) is a biomarker that may predict the occurrence of focal segmental glomerulosclerosis (FSGS); however, there is still controversy about whether suPAR can predict FSGS. In this study, we performed a systematic evaluation and meta-analysis to prove whether suPAR can predict FSGS, and to detect a threshold concentration of suPAR that can be used to diagnose FSGS. In addition, a threshold concentration of suPAR for the diagnosis of FSGS was proposed. DESIGN: Systematic review and meta-analysis. DATA SOURCES: We systematically searched PubMed, Embase, Cochrane Library, Web of Science and China Biology Medicine databases for studies published from the inception dates to 1 December 2018. ELIGIBILITY CRITERIA: (1) Data involving the suPAR level were from blood samples; (2) FSGS was diagnosed by biopsy; and (3) randomised controlled trials, cohort studies, case–control studies and cross-sectional studies. DATA EXTRACTION AND SYNTHESIS: Initially, a total of 364 studies were searched, among which 29 studies were finally included. In addition, seven studies described the cut-off value of suPAR, which ranged from 2992.6 to 5500 pg/mL. RESULTS: The results showed that the suPAR levels in the primary FSGS group were significantly higher when compared with that in the normal control group (p<0.001; standard mean difference (SMD): 2.56; 95% CI 1.85 to 3.28), and significant differences were observed in the secondary FSGS and in the normal control group (p<0.001; SMD: 1.68; 95% CI 1.37 to 1.98). A suPAR concentration of 3000 pg/mL may be the best threshold for the diagnosis of primary FSGS (sensitivity=0.72; specificity=0.88; area under the curve=0.85). CONCLUSION: Our results suggested that suPAR might be a potential biomarker for predicting primary and secondary FSGS. In addition, our data showed that a suPAR concentration of 3000 pg/mL might be used as a threshold for the diagnosis of FSGS. TRIAL REGISTRATION NUMBER: CRD42019120948. BMJ Publishing Group 2019-10-07 /pmc/articles/PMC6797292/ /pubmed/31594897 http://dx.doi.org/10.1136/bmjopen-2019-031812 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Renal Medicine Shuai, Tiankui Pei Jing, Yan Huang, Qiangru Xiong, Huaiyu Liu, Jingjing Zhu, Lei Yang, Kehu Jian, Liu Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis |
title | Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis |
title_full | Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis |
title_fullStr | Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis |
title_full_unstemmed | Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis |
title_short | Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis |
title_sort | serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis |
topic | Renal Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797292/ https://www.ncbi.nlm.nih.gov/pubmed/31594897 http://dx.doi.org/10.1136/bmjopen-2019-031812 |
work_keys_str_mv | AT shuaitiankui serumsolubleurokinasetypeplasminogenactivatedreceptorandfocalsegmentalglomerulosclerosisasystematicreviewandmetaanalysis AT peijingyan serumsolubleurokinasetypeplasminogenactivatedreceptorandfocalsegmentalglomerulosclerosisasystematicreviewandmetaanalysis AT huangqiangru serumsolubleurokinasetypeplasminogenactivatedreceptorandfocalsegmentalglomerulosclerosisasystematicreviewandmetaanalysis AT xionghuaiyu serumsolubleurokinasetypeplasminogenactivatedreceptorandfocalsegmentalglomerulosclerosisasystematicreviewandmetaanalysis AT liujingjing serumsolubleurokinasetypeplasminogenactivatedreceptorandfocalsegmentalglomerulosclerosisasystematicreviewandmetaanalysis AT zhulei serumsolubleurokinasetypeplasminogenactivatedreceptorandfocalsegmentalglomerulosclerosisasystematicreviewandmetaanalysis AT yangkehu serumsolubleurokinasetypeplasminogenactivatedreceptorandfocalsegmentalglomerulosclerosisasystematicreviewandmetaanalysis AT jianliu serumsolubleurokinasetypeplasminogenactivatedreceptorandfocalsegmentalglomerulosclerosisasystematicreviewandmetaanalysis |